The clearest statement about how dietary supplements are overseen in the United States comes from the official who ran the oversight. Speaking in an FDA interview, Cara Welch, then director of the agency’s Office of Dietary Supplement Programs, said: “FDA has no systematic way of knowing when new dietary supplements are introduced to the market or what they contain.”
She added that the agency has “limited resources to analyze the composition of dietary supplements.”
That is the regulator describing its own field of view, not a critic’s characterisation. And it reframes the question most people have, which is not whether supplements are regulated. They are. The question is which specific things get checked, by whom, and at what coverage. Those answers exist, they are published, and they come with dates attached.
This article is the map. It covers what happens before a product is sold, the six mechanisms that operate after it is sold, what each of those mechanisms can and cannot catch, how the numbers compare with the size of the market, and the one legislative request that has been pending since 2009. Other articles in this library handle the certification programmes, product testing surveys, manufacturing standards, proprietary blends, contamination and deceptive seals in detail. This one is about the structure they all sit inside.
Before a supplement is sold, almost nothing happens
FDA states this in several places and in several ways, and the wordings differ in useful ways.
On its dietary supplements question-and-answer page, current as of 27 August 2026, the agency says that under the Dietary Supplement Health and Education Act it does not have the authority to approve dietary supplements before they are marketed, and that it does not test supplements before they are sold to consumers. Its consumer explainer, FDA 101, says the agency does not have the authority to approve supplements for safety and effectiveness, with FDA’s own capitals on the word not, and describes its role as primarily beginning after a product enters the marketplace. Its page for consumers using supplements adds the sharpest version: in many cases, firms can lawfully introduce dietary supplements to the market without even notifying FDA.
The legal structure behind that is simple to state. A drug must be shown to be safe and effective before it is sold. A supplement must not be adulterated or misbranded, and the company, not the agency, is responsible for making sure it is not. Nobody reviews the product first.
One narrow exception exists, and it is the most misunderstood part of the system.
Six mechanisms, and what each one misses
Facility registration
Food facilities, which includes supplement facilities, register with FDA. Registration tells the agency a plant exists. It is not an approval and not an endorsement, and the regulation says so in those terms. What “FDA registered” does and does not mean on a label is covered in the companion article on misleading certifications.
Inspection
FDA inspects supplement manufacturing facilities against the manufacturing rules. The internal programme that governs this work, Compliance Program 7321.008, was issued on 18 August 2025 with an implementation date of 30 September 2024, and it is more revealing than its title suggests.
It defines four different inspection types: a full-scope manufacturing inspection, a distributor inspection, a warehouse inspection and a packaging and labelling inspection. A distributor inspection covers firms that are ultimately responsible for putting their brand of finished supplements into commerce, and it applies specifically to firms that contract out some or all of their manufacturing.
Follow that through and a common assumption breaks. When a brand says its facility has been inspected, that may mean an inspection of an office and a distribution operation, not of the plant that made the capsules. An inspection of the company and an inspection of the factory are different events. The programme sets no numeric target for how many inspections to perform in a year; it works from a list of firms due for inspection under the frequencies set by food safety law.
Notification of a new ingredient
If a manufacturer wants to use a dietary ingredient that was not marketed in the United States before 15 October 1994, it must notify FDA at least 75 days before introducing the product.
Here is the part that gets misread. FDA’s own labeling guide states that failure of the agency to respond to a notification does not constitute a finding by the agency that the ingredient or the supplement containing it is safe or is not adulterated. Silence is not clearance. A company that submits a notification and hears nothing has satisfied a procedural requirement, not obtained an opinion.
Adverse event reports
Companies must report serious adverse events. Consumers and clinicians can report voluntarily.
The Government Accountability Office measured what that produces. In a report published on 18 March 2013, GAO found that FDA received 6,307 adverse event reports for dietary supplements from 2008 through 2011, with 71 percent coming from industry as serious events required by law. Over a shorter window, 2008 to 2010, poison control centers received over 1,000 more reports of supplement-linked adverse events than FDA did for the same period.
GAO also found that FDA does not systematically collect information on how it uses those reports for consumer protection actions, and agency officials said most reports do not support action because the information in them is limited. Tied to adverse event reporting violations over that period, FDA issued three warning letters, one injunction and 15 import refusals. GAO’s recommendation that FDA track how it uses these reports was later closed as not implemented.
Labelling
FDA reviews labels and other labelling, including websites. Whether that review reaches the claims it is supposed to reach was audited independently.
The HHS Office of Inspector General examined 127 dietary supplements marketed for weight loss or immune support and issued its report on 2 October 2012. It found that the substantiation documents companies held for their claims were inconsistent with FDA guidance on competent and reliable scientific evidence. Seven percent of products lacked the disclaimer the law requires. Twenty percent carried prohibited disease claims on the label. And the finding that matters most for this article is that the inspectors could not readily establish, from FDA’s own records, whether manufacturers had even filed the notification their claims required.
OIG recommended that FDA seek statutory authority to review the substantiation behind structure and function claims. FDA did not explicitly concur and said it would consider it. That recommendation was closed as unimplemented on 31 May 2017. The taxonomy of claim types is covered in a separate article.
Post-market enforcement
FDA can request a voluntary recall, issue a public notification, send a warning letter, refuse an import, seize a product or seek an injunction. It gained the power to order a recall of most foods, including supplements, only on 4 January 2011, through section 206(a) of the Food Safety Modernization Act. How rarely that power has been used, and on what, is the subject of article 350.
The coverage figures, with their years
Set the mechanisms against the market and the picture resolves. Every figure below has a year and a primary source.
| What was measured | Figure | Year | Source |
|---|---|---|---|
| Inspection frequency | High-risk supplement firms inspected about once every 3 years, other firms about once every 5 | 2018 | GAO-19-23R |
| Firm inspections | 410 inspections from 1 January to 30 September 2012, up from 120 in 2008 | 2013 | GAO-13-244 |
| Pesticide monitoring | 6 dietary supplement samples in the entire fiscal year, all imports, 1 of them violative | FY2023 | FDA pesticide residue monitoring report |
| Adverse event reports | 6,307 received over four years, while poison centers received over 1,000 more than FDA did over three | 2013 | GAO-13-244 |
| Mandatory recall authority | Held since 4 January 2011; one enforcement action initiated across FY2011 to FY2013 | 2014 | FDA reports to Congress |
| Drug-adulterated products | Of 776 products FDA identified from 2007 through 2016, 7 drew a warning letter to the firm | 2018 | JAMA Network Open |
The pesticide line deserves a sentence of its own, because it is the cleanest illustration in the set. FDA’s pesticide residue monitoring programme for fiscal year 2023 does carry dietary supplements, but only as two subcategories inside the import appendix, one for botanical and herbal supplements and one labelled simply other, both filed under other food products. The domestic appendix has no supplement category at all. Two samples fell under the botanical and herbal heading and four under the other one, and one of those four came back violative. The report classifies it as a no-tolerance violation, which means a residue turned up for a pesticide and commodity pairing that has no federal tolerance at all, rather than a residue above an existing limit. Programme-wide, violative residues turned up in 2.8 percent of domestic samples and 13.5 percent of import samples, so the programme itself is real and finds things. It simply almost never looks at this category.
Two cautions about reading that table. Six samples is far too few to say anything about how contaminated supplements are, and one violative result out of six is not a violation rate; these figures describe surveillance, not prevalence. And the inspection numbers are more than a decade old because no current FDA-published count of supplement facility inspections could be located in a primary source for this article. The annual inspections report to Congress covers drug and device establishments only.
Nobody knows how many products there are, including FDA
The product count is quoted everywhere as a settled fact. It is not one, and the reason it is not one is the point.
FDA officials told GAO that the market grew from about 4,000 products in 1994 to about 80,000 in 2016. The director of FDA’s dietary supplement programmes described a marketplace of over 100,000 products, in content current as of March 2024. In January 2026, the office of the senator who introduced supplement listing legislation stated that FDA estimates more than 100,000 products are on the market.
These are not strictly contradictory. They are different years. But all three are FDA estimates of a number the same agency says it cannot systematically know, because no federal requirement obliges anyone to tell FDA that a product exists. GAO put the structural reason plainly in 2018: federal law does not require that dietary supplements be listed with FDA or another federal agency, so there is no definitive data source on the market.
Treat the count as a range with a known source of error rather than a statistic. The honest version is that the market went from a few thousand products to somewhere around or above a hundred thousand over three decades, and that nobody holds a list.
The FTC handles advertising, FDA handles the label
Two federal agencies share this work, and knowing which is which determines where a complaint should go.
The Federal Trade Commission told the Senate Special Committee on Aging in May 2010 that it has concurrent jurisdiction over dietary supplements with FDA. Under a long-standing liaison agreement, FTC has primary authority over the advertising of foods including supplements, and FDA has primary responsibility for their labelling. FTC’s current Health Products Compliance Guidance, published on 20 December 2022 and replacing a 1998 guide, repeats the split: FDA has primary responsibility for claims in labelling, FTC for claims in all forms of advertising.
The two agencies also have different tools. FTC can compel a company to produce the evidence behind a claim and can ask a court for restraining orders and asset freezes. FDA can seize products and seek destruction of misbranded goods.
GAO looked at how well this division is communicated and was unimpressed. In a report published on 16 May 2017, it found that few documents explicitly delineate the agencies’ differing roles, that the agencies rarely communicate those roles to industry or consumers, and that consumer groups were unclear which agency oversees online supplement marketing. GAO recommended joint consumer guidance; both agencies concurred, and in July 2017 they published joint blog posts explaining their respective roles and where to direct complaints. That recommendation is recorded as closed and implemented.
One more thing FTC’s guidance settles, and it surprises people. Complying with the notification and disclaimer provisions of the supplement law does not amount to FDA authorisation, so an advertiser should not imply that FDA has specifically approved a claim on that basis.
What a state attorney general can do
Federal agencies are not the only enforcers, and a state can move on a different legal theory.
On 22 October 2015, the Oregon Department of Justice announced a lawsuit against a national supplement retailer, alleging that it misrepresented certain products as lawful dietary supplements when they were in fact unapproved drugs. The ingredients at issue were picamilon, a synthetic compound not approved in the United States, and BMPEA, a stimulant; products labelled as containing a particular botanical were alleged to be spiked with undeclared BMPEA. The complaint described thousands of units sold across 25 Oregon stores over roughly two years.
The vehicle was the Oregon Unlawful Trade Practices Act, a state consumer protection statute, not federal food and drug law. That is the structural point: a state attorney general can sue a retailer for selling products it alleges are unapproved drugs without waiting for FDA to act first, and can seek civil penalties and restitution. The outcome of that particular case could not be verified from a primary source for this article, so it is reported here as a filed action rather than a result.
The same recommendation, seventeen years later
The single clearest throughline in the record is a request that has not been granted.
On 29 January 2009, GAO published a report recommending, among other things, that FDA be given authority to require supplement companies to register as supplement firms, to list their products and labels with annual updates, and to report all adverse events. FDA did ask for that authority through the food safety legislation that became law in 2011, and expanded its registration categories to include supplements. GAO closed the recommendation as implemented, because FDA made the request. But GAO also recorded that the broader requirements did not become law, noting that the reporting requirement had been part of multiple proposed legislative efforts without being enacted.
A second recommendation from that same 2009 report, that FDA clarify when an ingredient counts as new, was closed as not implemented. Draft guidance issued in July 2011 had still not been finalised as of December 2017.
Seventeen years on, the same ask is back. On 15 January 2026, S. 3677, the Dietary Supplement Listing Act of 2026, was introduced in the Senate, read twice and referred to the Committee on Health, Education, Labor, and Pensions. A House companion, H.R. 8370, carrying the same short title, was introduced on 20 April 2026 and referred to the Committee on Energy and Commerce. Both would require manufacturers to list their products with FDA, submitting product names, a full ingredient list, an electronic copy of the label, allergen statements and the health and structure or function claims being made, in a database open to the public.
As of 21 October 2026, the Government Publishing Office publishes only the as-introduced version of each bill, which is consistent with no committee report and no floor action. That is strong but not conclusive evidence, because committee activity short of a reported bill cannot be ruled out from that source alone, and bill status changes. Check the current status before relying on it.
What is not in dispute is the route. In 2009 GAO’s recommendation was that FDA ask Congress for the authority rather than write a rule, and FDA asked. The same approach is in front of the same committees now.
How to use this when you are standing in the aisle
The practical translation of all of the above is short.
Nothing on a package tells you a federal agency examined the product. No mark, no registration number and no notification receipt carries that meaning, and FDA has said so in plain language on pages written for consumers.
What that leaves is a sequence worth running in order. First, decide whether the ingredient has evidence behind it for your situation, which is a question about the research, not about the label. Second, decide whether the product plausibly contains what it says, which is where independent certification programmes do real and limited work. Third, and most important for safety, take the actual container to a pharmacist or clinician if you use prescription medicines, are pregnant or breastfeeding, have kidney or liver disease, or are scheduling surgery. Those are the situations where an interaction or an excess does measurable harm, and they are the situations a label cannot help with.
And treat one event as a reason to act rather than to wait. If symptoms begin after starting a supplement, particularly yellowing of the skin or eyes, dark urine, chest pain, an irregular heartbeat, fainting, severe abdominal pain or unexplained bruising, seek medical attention and bring the bottle. The adverse event reporting system that FDA relies on is fed by reports like that, and GAO’s own finding is that poison centers hear about more of these events than FDA does.
Sources
- US Food and Drug Administration. “FDA’s Regulation of Dietary Supplements with Dr. Cara Welch (content current as of 5 March 2024).” fda.gov
- US Food and Drug Administration. “Questions and Answers on Dietary Supplements (content current as of 27 August 2026).” fda.gov
- US Food and Drug Administration. “FDA 101: Dietary Supplements.” fda.gov
- US Food and Drug Administration. “Information for Consumers on Using Dietary Supplements.” fda.gov
- US Food and Drug Administration. “Dietary Supplement Labeling Guide: Chapter VII. Premarket Notification of New Dietary Ingredients.” fda.gov
- US Food and Drug Administration. “Compliance Program 7321.008, Dietary Supplements – Foreign and Domestic Inspections, Sampling, and Imports (issued 18 August 2025).” fda.gov
- US Food and Drug Administration. “Pesticide Residue Monitoring Program Fiscal Year 2023 Pesticide Report.” fda.gov
- US Food and Drug Administration. “Annual Report to Congress on the Use of Mandatory Recall Authority – 2014.” fda.gov
- US Government Accountability Office. “GAO-09-250, Dietary Supplements: FDA Should Take Further Actions to Improve Oversight and Consumer Understanding (29 January 2009).” gao.gov
- US Government Accountability Office. “GAO-13-244, Dietary Supplements: FDA May Have Opportunities to Expand Its Use of Reported Health Problems to Oversee Products (18 March 2013).” gao.gov
- US Government Accountability Office. “GAO-19-23R, Memory Supplements: Results of Testing for Selected Supplements (18 October 2018).” gao.gov
- US Government Accountability Office. “GAO-17-416, Memory Supplements: Clarifying FDA and FTC Roles Could Strengthen Oversight and Enhance Consumer Awareness (16 May 2017).” gao.gov
- HHS Office of Inspector General. “OEI-01-11-00210, Dietary Supplements: Structure/Function Claims Fail To Meet Federal Requirements (2 October 2012).” oig.hhs.gov
- US Federal Trade Commission. “Health Products Compliance Guidance (December 2022).” ftc.gov
- US Government Publishing Office. “S. 3677, Dietary Supplement Listing Act of 2026 (introduced 15 January 2026).” govinfo.gov
- US Government Publishing Office. “H.R. 8370, Dietary Supplement Listing Act of 2026 (introduced 20 April 2026).” govinfo.gov
- Oregon Department of Justice. “Oregon files lawsuit against GNC for selling nutritional supplements with ingredients not approved in U.S. (22 October 2015).”
- JAMA Network Open. “Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. “Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings.” JAMA Network Open, 2018. PubMed. DOI: 10.1001/jamanetworkopen.2018.3337.” doi.org
- JAMA Network Open. “Cohen PA. “The FDA and Adulterated Supplements—Dereliction of Duty.” Invited commentary, JAMA Network Open, 2018. PubMed. DOI: 10.1001/jamanetworkopen.2018.3329.” doi.org